| 0.23 0.059 (34.5%) | 01-30 12:25 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.53 |
1-year : | 0.63 |
| Resists | First : | 0.45 |
Second : | 0.54 |
| Pivot price | 0.42 |
|||
| Supports | First : | 0.31 | Second : | 0.26 |
| MAs | MA(5) : | 0.36 |
MA(20) : | 0.42 |
| MA(100) : | 0.58 |
MA(250) : | 1.8 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 11 |
D(3) : | 20.6 |
| RSI | RSI(14): 35.9 |
|||
| 52-week | High : | 7.3 | Low : | 0.31 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ LIPO ] has closed above bottom band by 15.7%. Bollinger Bands are 52.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.36 - 0.36 | 0.36 - 0.36 |
| Low: | 0.34 - 0.35 | 0.35 - 0.35 |
| Close: | 0.35 - 0.35 | 0.35 - 0.35 |
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.
Thu, 18 Sep 2025
Lipella Pharmaceuticals Announces Positive Final Results from Phase 2a Study of LP-10 in Oral Lichen Planus - GlobeNewswire
Wed, 25 Jun 2025
Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting - Yahoo Finance
Fri, 20 Jun 2025
Lipella Pharmaceuticals(NASDAQ:LIPO) Faces Decline in Biotech Sector Nasdaq Composite - Kalkine Media
Fri, 20 Jun 2025
Lipella stock tumbles after Nasdaq delisting over rule violations - Investing.com
Fri, 20 Jun 2025
Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market - GlobeNewswire
Fri, 28 Mar 2025
Lipella Pharmaceuticals Inc. (LIPO) reports earnings - qz.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 4.33e+006 (%) |
| Held by Institutions | 6.5 (%) |
| Shares Short | 133 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.59e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 564.1 % |
| Return on Equity (ttm) | -118.5 % |
| Qtrly Rev. Growth | 470160 % |
| Gross Profit (p.s.) | -24.57 |
| Sales Per Share | -335.96 |
| EBITDA (p.s.) | -7.04348e+006 |
| Qtrly Earnings Growth | -3.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | -0.05 |
| Dividend | 0 |
| Forward Dividend | 100090 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|